A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma

EJNMMI Research

Table 1 Clinical features of 30 ACC patients

No.	Sex	Age	Pathological classification	Involvement of ACC	Stage	Treatment history	Time interval (month)
1	F	53	Cribriform	Maxillary sinus	Primary	None	1
2	F	29	Solid	Larynx	LR	I	99
3	F	54	Cribriform	Nasopharynx	LR	I + II	52
4	M	23	Solid	Bone	LR + DS	I + II + III	8
5	M	47	Solid	Maxillary sinus; liver; bone	LR + DS	I + II + III + IV	19
6	M	34	Cribriform	Maxillary sinus; lung	LR + DS	I + II + III	95
7	M	49	Cribriform	Maxillary sinus; lung	LR + DS	I + II + III	74
8	F	60	Solid	Maxillary sinus; brain; lung; bone	LR + DS	I + II + III	127
9	M	62	Solid	Maxillary sinus; lung; bone; liver	LR + DS	I + II + III + IV	21
10	M	56	Solid	Maxillary sinus; lung; bone; liver	LR + DS	I + II + III	12
11	F	41	Solid	Meninx	DS	I + III	20
12	F	31	Mixed	Lung	DS	I + II + III	61
13	M	32	Cribriform	Lung; bone	DS	I + II + III + IV	75
14	M	32	Mixed	Lung	DS	I + II + III + IV	37
15	M	34	Tubular	Lung; liver; bone; lymph node	DS	I + II + III + IV	124
16	F	28	Cribriform	Lung	DS	I + II + III + IV	127
17	F	39	Mixed	Lung	DS	I + II + III	118
18	M	28	Cribriform	Lung	DS	I + II + III + IV	99
19	M	53	Cribriform	Lung	DS	I + II + III	56
20	M	42	Cribriform	Lung	DS	I + II + III + IV	51
21	M	39	Mixed	Lung	DS	I + II + III + IV	35
22	M	54	Tubular	Lung	DS	I + II + III	84
23	F	30	Cribriform	Lung	DS	I + II + III + IV	154
24	F	45	Solid	Lung	DS	I + II + III	37
25	M	49	Solid	Lung	DS	I + II + III + IV	38
26	F	56	Solid	Bone	DS	I + II + III + IV	109
27	F	25	Cribriform	Lung	DS	I + II + III + IV	25
28	F	44	Cribriform	Lung	DS	I + II + III + IV	51
29	F	66	Mixed	Lung	DS	I + II + IV	60
30	F	54	Cribriform	Lung	DS	I + II + III + IV	60

I surgery; II radiotherapy; III chemotherapy; IV targeted therapy
ACC adenoid cystic carcinoma, Time interval time interval from diagnosis to PET/CT, LR local recurrence, DS distant metastases